Citations

Clear

2358 citation(s) found for "Yu, Long".

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)
Pittock, Sean, Barnett, Michael, Bennett, Jeffrey, Berthele, Achim, Seze, Jérôme de, Levy, Michael, Oreja-Guevara, Celia, Palace, Jacqueline, Paul, Friedemann, Allen, Kerstin, Parks, Becky, Kim, Ho Jin, Pittock, Sean J. , Barnett, Michael , Bennett, Jeffrey, Berthele, Achim , Seze, Jerome De , Levy, Michael , Nakashima, Ichiro , Oreja‐Guevara, Celia , Palace, Jacqueline , Paul, Friedemann , Pozzilli, Carlo , Allen, Kerstin , Parks, Becky , Kim, Ho Jin

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215493 Get It

Systemic immune-inflammation and response indices is associated with early but not long-term survival after primary stereotactic radiosurgery for brain metastases
Hong, Sukwoo , Takami, Hirokazu, Umekawa, Motoyuki , Hasegawa, Hirotaka, Kawashima, Mariko , Takayanagi, Shunsaku , Tanaka, Shota, Saito, Nobuhito, Takami, Hirokazu , Shinya, Yuki , Hasegawa, Hirotaka , Kitagawa, Yosuke , Nomura, Masashi , Saito, Nobuhito

Mayo Clinic

British Journal of Neurosurgery | June 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/02688697.2026.2682819 | PMID 42267963 Get It

Long-term eculizumab treatment failure in C3 glomerulonephritis: two case reports
Soler, María José , Cara, Anila, Sethi, Sanjeev , Appel, Gerald B, Santoriello, Dominick , Santos, Fernanda Dos, Fervenza, Fernando C. , Zubidat, Dalia , Soler, Maria Jose , Cara, Anila , Sethi, Sanjeev , Dos Santos, Fernanda G, Fervenza, Fernando C , Appel, Gerald B.

Mayo Clinic

Clinical Kidney Journal | June 9, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1093/ckj/sfag189 | PMID 42415834 Get It

ABSTRACT C3 glomerulonephritis (C3GN) is a rare kidney disease driven by dysregulation of the alternative complement pathway. We report two challenging cases of patients with C3GN in whom various immunosuppressant therapies have failed to achieve complete remission, prompting treatment with eculizumab, an anti-C5 humanized monoclonal antibody that inhibits the terminal complement pathway. Although transient improvement in kidney function was observed, both patients eventually experienced worsening renal parameters, with increasing proteinuria and hematuria, culminating in progression to end-stage kidney disease. Repeated kidney biopsies following eculizumab therapy demonstrated persistent, granular mesangial and capillary wall C3 (3+) staining on immunofluorescence studies, indicating ongoing complement activation upstream of the C5 blockade and the perpetuation of C3 deposits in the glomeruli. These cases underscore the limited efficacy of terminal complement inhibition in halting disease progression in C3GN.
Educator's Blueprint: Optimizing the Resident Research Experience
Gottlieb, Michael , Gawel, Richard J , Jordan, Jaime , Long, Brit , Landry, Adaira , Gottlieb, Michael , Long, Brit

Mayo Clinic

AEM Education and Training | June 9, 2026 | Volume: 10 | Issue: 3 | Pages: No page available

10.1002/aet2.70212 | PMID 42273402 Get It

ABSTRACT Research is important to advance the field of emergency medicine and improve patient care. As such, emergency medicine residents are required to complete a scholarly project during their training. This experience provides an opportunity to enhance their exposure to research, expanding their skillset as both producers and consumers of the medical literature. However, the process may be overwhelming to launch, especially for residents. This Educator's Blueprint will provide 10 strategies for navigating and optimizing the resident research experience. These strategies include providing structured training, creating a research‐supportive environment, selecting a project using resident‐centric FINER criteria, identifying a research mentor, creating mosaic research experiences, setting expectations, empowering residents, selecting team members for sustainability, providing scaffolding and support during the writing stage, and explaining the peer review process and normalizing rejection or revisions. These strategies will help guide faculty seeking to enhance their learners' research experience.
Persistent Cerebral 18-FDG PET Changes in Patients With Long COVID Presenting With Fatigue and Post Exertional Malaise
Ganesh, Ravindra , Nair, Kaavya, Grach, Stephanie L. , Croghan, Ivana T. , Yadav, Siddhant, Mueller, Michael , Hurt, Ryan T. , Mueller, Michael R , Ganesh, Ravindra , Grach, Stephanie L , Nair, Kaavya

Mayo Clinic

Journal of Primary Care & Community Health | June 9, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261458748 | PMID 42259512 Get It

Objective Long COVID (LC) refers to the long-term symptoms occurring after SARS-CoV-2 infection and resolution of the initial disease prodrome. While LC is increasingly recognized, knowledge about its biomarkers is still limited. This study examines imaging findings in 18 F-FDG PET-CT scans in 40 patients with LC from an academic LC Clinic, for potential imaging biomarkers. Methods This study included patients aged 18 and older with confirmed positive SARS-CoV-2 PCR test and at least 28 days post-symptom onset. 18 F-FDG PET-CT scans were performed, and brain metabolic activity was compared to a control database to generate Z-scores. Participants were grouped based on their clinical phenotype and Z-scores of different brain regions were analyzed using t-tests. Results The study group was mainly female (70%), with a median age of 53 years, and predominantly non-Hispanic White (90%). Most had pre-existing conditions such as gastrointestinal, cardiovascular, endocrine, and psychiatric disorders. The findings showed significant cerebral hypometabolism in 29 patients with fatigue and post-exertional malaise (PEM), particularly in the left sensorimotor cortex (p=0.0253) and bilateral primary visual cortex (right: p=0.0096, left: p=0.0016), which persisted up to two years after infection. Conclusions In summary, this study identified persistent cerebral hypometabolism in LC patients, especially those with fatigue with PEM, up to two years post-infection. These results suggest that 18 F-FDG PET-CT could be a valuable tool for diagnosing and managing LC. Further research is essential to confirm these findings and improve treatment strategies for patients with LC.
Mirikizumab Demonstrates Long-Term Efficacy on Histological Resolution in the Phase 3, Multicenter, Open-Label VIVID-2 Extension Study
Reinisch, W, Jairath, V, Protic, M, Hertogh, G De, Harpaz, N, Hisamatsu, T, D'Haens, G, Pai, R, Morris, N, Hozak, R, Yu, G, Durand, F, Magro, F, Reinisch, W, Protić, Marijana , Hertogh, G De, Harpaz, Noam , Hisamatsu, Tadakazu, D’Haens, Geert , Pai, Rish, Morris, Nathan , Hozak, Rebecca R., Durand, Frédérick

Mayo Clinic

Zeitschrift für Gastroenterologie | June 8, 2026 | Volume: 64 | Issue: 05 | Pages: e139-e140

10.1055/s-0046-1823082 Get It

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis
Steinhardt, Maximilian J., Hegenbart, Ute , Hellou, Tamer , Oubari, Sara, Roussel, Murielle , Schwotzer, Rahel , Buadi, Francis, Dingli, David, Kourelis, Taxiarchis, Zanwar, Saurabh , Rieger, Max J., Morbach, Caroline, Cejka, Vladimir , Störk, Stefan, Einsele, Hermann, Kumar, Shaji, Gertz, MA, Carpinteiro, Alexander , Kortum, K. Martin, Dispenzieri, Angela, Steinhardt, Maximilian , Steinhardt, Maximilian , Zanwar, Saurabh S , Rieger, Max J , Cejka, Vladimir , Gertz, Morie A , Muchtar, E , Hegenbart, Ute , Roussel, Murielle , Buadi, Francis K. , Dingli, David , Binder, Moritz , Kourelis, Taxiarchis , Morbach, Caroline , Gerber, B. , Störk, Stefan , Kumar, Shaji, Gertz, Morie A. , Kortüm, Martin , Muchtar, Eli , Dispenzieri, Angela , Schönland, Stefan

Mayo Clinic

American Journal of Hematology | June 8, 2026 | Volume: 101 | Issue: 8 | Pages: 1903-1914

10.1002/ajh.70371 | PMID 42252535 Get It

ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM within 12 months at six centers in Europe and the United States between 2010 and 2024 to evaluate outcomes by baseline risk factors, hematologic response, and receipt of HDM. Death was an equally competing risk after the 12‐month landmark chosen to address early non‐proportional hazards and to ensure completion of first‐line therapy. BMPC > 20% was associated with inferior outcomes (HR 1.7), and gain/amp 1q with shorter TTP (HR 2.15), whereas other high‐risk FISH abnormalities were not. In multivariable models, VGPR/CR after standard intensity therapy was associated with longer TTP (HR 0.49/0.29), while gain/amp 1q remained independently associated with shorter TTP (HR 2.18). Receipt of daratumumab and HDM were associated with longer TTP (HR 0.44/0.61). HDM benefited patients who had not achieved CR after standard intensity therapy (mTTP 21.0 vs. 5.7 months without HDM), whereas patients already in CR did not benefit. Higher BMPC at diagnosis was associated with earlier progression in patients not receiving HDM (HR 1.9 for 5%–20% and 4.09 for > 20%), a risk attenuated in the HDM cohort. Gain/amp 1q remained associated with shorter TTP regardless of HDM exposure. These findings support a selective role for HDM, primarily benefiting patients with residual disease after standard intensity therapy or higher BMPC burden at diagnosis.
Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.
Giridhar, Karthik, McDonnell, Charles H. , Kurbegov, Dax, Matrana, Marc , Gadgeel, Shirish M., Kim, Raymond, Stipec, Gretchen, Oeffinger, Kevin C., Demeure, Michael J. , Lillard, James W., Kaltman, Rebecca , Tran, Jennifer, Roth, Alan , TAHHAN, SAMI, Richards, Donald A., Lopatin, Rita, Marquez, Celine, Nabavizadeh, Nima , Gadgeel, Shirish M. , Oeffinger, Kevin C. , Lillard, James W., Tahhan, Sami, Poklepovic, Andrew , Richards, D., McCusker, Margaret

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba10509 Get It

LBA10509 Background: The MCED test (Galleri) detects a shared cancer signal from cell-free DNA in blood and predicts a cancer signal origin (CSO) to guide diagnostic (dx) workup. PF2 (NCT05155605) is a large, prospective, multicenter, interventional study of the MCED test’s performance and safety in a diverse US intended-use population. Methods: PF2 enrolled participants aged ≥50y without clinical suspicion of cancer or cancer diagnosis/treatment within 3y of enrollment. Primary objectives were MCED performance and safety in terms of dx testing triggered by a positive (cancer signal detected) MCED test result. Participants with a positive MCED test underwent targeted dx workup guided by the predicted CSO(s). Participant-reported anxiety was assessed with the State Trait Anxiety Inventory. Results: PF2 enrolled 35,878 participants; 32,007 with a 12m cancer assessment were analyzable for performance. Of 287 (0.9%) with a positive MCED test, 173 were diagnosed with cancer within 12m, for a cancer detection rate of 0.5% (95% CI 0.5-0.6%) and positive predictive value of 60.3% (54.5-65.8%). Specificity was 99.6% (99.6-99.7%). 12m episode sensitivity was 69.8% (62.8-76.0%) in a prespecified subgroup of 12 cancers responsible for ⅔ of US cancer deaths, 66.2% (55.1-75.8%) in a subgroup of 6 aggressive cancers with low 5y survival, and 39.3% (34.9-44.0%) across all cancers. Overall CSO prediction accuracy was 91.3% (86.2-94.7%) across all cancers. The MCED test detected 151 new primary and 22 recurrent cancers; additional cancers detected by screening were those with USPSTF A/B (n=31) and C (n=60) recommended screening. Of 151 MCED-detected new primaries, 80 (53.0%) were clinical stage I-II; 107 (70.9%) were stage I-III. Of 80 MCED-detected stage I-II cancers, 71.2% had no USPSTF A/B screening recommendation. Of 35,335 participants analyzable for safety, 213 (0.6%) had invasive procedure(s) to evaluate a positive MCED test result, of which 90% were nonsurgical and 1.8x more likely for participants with vs without cancer diagnosis. Most (87.6%) had a CSO-guided dx evaluation. There were 5 study-related adverse events during the time of dx workup; none were serious. Anxiety temporarily increased for participants with a positive MCED test and cancer diagnosed, and returned to baseline by 12m. Of participants with a positive MCED test, median time from test result to dx resolution was 48d (95% CI 43-56). Few participants (7/63 [11.1%]) had cancer found by dx PET/CT after a targeted dx workup that did not reveal cancer. Conclusion: The MCED test demonstrated robust performance with a favorable safety profile. When MCED testing was added to USPSTF A/B screening, 6.5x more cancers were detected by screening, most at early stages. The diverse, representative PF2 participant population supports the generalizability of these findings to the US intended-use population. Clinical trial information: NCT05155605 .
Risk of recurrent spontaneous preterm birth among those with persistent cervical HPV infection
Weng, Jessica , Shahi, Maryam , Norgan, Andrew, Enninga, Elizabeth Ann L. , Long, Margaret, Larish, Alyssa M.

Mayo Clinic

No container title available | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9861232/v1 | PMID 42282036 Get It

Abstract Background Preterm premature rupture of membranes (PPROM) and preterm labor (PTL) are adverse obstetrical outcomes that are strongly associated with cervical high-risk human papilloma virus (cHPV) infection at the time of pregnancy. Persistent cHPV may lead to oncogenic changes in the cervico-vaginal tract and can cause inflammation in gestational tissues, but it is unknown how persistent cHPV infection may affect obstetrical outcomes. The aim of this study is to evaluate whether persistent cHPV infection is associated with recurrent PPROM or PTL among patients with a prior spontaneous preterm birth due to PPROM/PTL, and to examine clinical and pathologic characteristics of cHPV infection in this population. Methods We conducted a retrospective cohort study of patients delivering at Mayo Clinic Rochester or Mayo Clinic Health System (5/1/2018–12/31/2023). Eligible patients had ≥ 1 spontaneous preterm birth due to PPROM/PTL and positive cHPV testing. Demographics and pregnancy outcomes from index and subsequent pregnancies were abstracted. Persistent cHPV was defined as > 1 pregnancy with positive cHPV testing. Results Of 191 index pregnancies, 90 (47.1%) and 30 (33.3%) had one and two subsequent pregnancies, respectively. Patients were predominantly White (91.3%), non‑Hispanic (94.2%), non-smokers (72.0%), and 34.8% were unvaccinated for HPV. Approximately one‑third (31%) experienced recurrent PPROM/PTL in the second pregnancy, with recurrence in 40.7% of those with persistent cHPV and 27.4% without (p = 0.69). Excisional procedures occurred before 12.0% of index pregnancies and 20–24% of subsequent pregnancies; recurrence of PTL/PPROM remained high regardless of procedure history. HPV strain data were available for 132 index pregnancies, and types 16 and 18 were more likely to persist into a subsequent pregnancy (p = 0.0043). CIN persistence occurred at similar rates in patients with and without persistent cHPV infection. Placental inflammation rates were high in both patients with persistent and non-persistent cHPV. Conclusion Recurrent PPROM/PTL, CIN persistence, and placental inflammation were common; a finding independent of persistent cHPV infection, excisional procedure history, or HPV vaccination status. These findings suggest that factors other than cHPV persistence may play a larger role in recurrent preterm birth. Larger studies with higher cHPV prevalence and subsequent pregnancies are needed to provide clarity.
PubMetric : Empowering Researchers and Improving Systematic Reviews/Meta‐Analyses
Smith, Clay, Rouleau, S, Smith, Joshua, Long, Brit, Rouleau, Samuel G. , Rouleau, Samuel, Long, Brit

Mayo Clinic

Academic Emergency Medicine | May 30, 2026 | Volume: 33 | Issue: 6 | Pages: No page available

10.1111/acem.70326 | PMID 42216680 Get It